PharmacotherapyHumansReceptorsThrombopoietinRandomized Controlled Trials as TopicThromboembolism
Thromboembolic Risk of Thrombopoietin Receptor Agonists for Adult Primary Immune Thrombocytopenia: A Systematic Review and Meta-Analysis Integrating Randomized Controlled Trials and Prospective Evidence.
Meng-Fei Dai, Gao-Wei Chong, Wen-Xiu Xin, Si-Si Kong, Jun-Feng Zhu, Li-Ke Zhong, Gao-Qi Xu, Xiang-Yu Jin, Chao-Neng He, Ting-Ting Wang, Xiu-Fang Mi, Liping Luo, Zhu-Jin Song, Hai-Ying Ding, Luo Fang
Published: 202510.1002/phar.70075
Abstract
BACKGROUND: Although randomized controlled trials (RCTs) have established evidence regarding thromboembolic risks of thrombopoietin receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP) during short-term follow-up, the long-term risks remain u…
Preview only. Read the full abstract at the source